Bioanalytical Services and the importance of continuity:
- Removing lab variability from Discovery PK through to Phase IIb clinical studies (D2C)
- Tailoring rapid, fit-for-purpose methodology to support non-regulatory studies (PK, MTD and DRF)
- Development of fit-for-purpose methods into fully FDA and EMEA compliant assays to support regulatory studies (preclinical GLP support and clinical bioanalysis)
